Retatrutide
8 research papers indexed
FDA Concerns with Unapproved GLP-1 Drugs
0
RegulatorySourceRegulatory
Lilly PR — TRANSCEND T2D-1 Results 2026
0
Lilly Press Release
·2026Press ReleaseHumanType 2 diabetesSourcePress Release
Lilly PR — TRIUMPH-4 Results 2025
0
Lilly Press Release
·2025Press ReleaseHumanObesitySourcePress Release
Coskun 2022 — Retatrutide Discovery to Clinical PoC
0
Cell Metabolism
·2022Journal ArticleObesity and metabolic diseaseSourcePreclinical
Jastreboff 2023 — Retatrutide Phase 2 Obesity
0
New England Journal of Medicine
·2023RCTHumanObesitySourcePhase2
Sanyal 2024 — Retatrutide MASLD Study
0
New England Journal of Medicine
·2024RCTHumanMASLD/MASH with fibrosisSourceRCT
Rosenstock 2023 — Retatrutide Phase 2 T2D
0
Lancet
·2023RCTHumanType 2 diabetesSourceRCT
Coskun 2025 - Retatrutide Effects on Body Composition in Type 2 Diabetes
0
The Lancet Diabetes & Endocrinology
·2025Clinical TrialHumanType 2 diabetes and obesity-related body compositionSourceClinical Trial